HCRTR2

Across TCGA pan-cancer cohorts, HCRTR2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated HCRTR2 data layer compared with 17 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher HCRTR2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HCRTR2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where HCRTR2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.277	0.533	<.001	27	view →
HNSC	DFS	Quartile	IV	0.889	0.351	.009	14	view →
LSCC	OS	Median	All	0.933	0.719	.027	8	view →
GBM	OS	Quartile	All	0.782	0.995	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

HCRTR2–PDAC (DFS)

Open the PDAC breakdown →